纳斯达克： -- -- --

最近浏览

实时行情

意见反馈

诺华

NYSE:NVS 延时15分钟
  • 今开：--
    昨收：--
  • 今日区间：--
    52周区间：--
  • 成交量：--
    成交额：--
  • 市 值：--
    市盈率：--
  • 振幅：
    每股收益：
成交量

董事会

Hans J rg Reinhardt
Hans J rg Reinhardt currently works at Novartis, Inc., as Chairman from 2013, Novartis International AG, as Chairman-Supervisory Board, Novartis AG, as Chairman from 2013, Novartis Pharmaceuticals Corp., as Chairman, Novartis Institutes for Biomedical Research, Inc., as Chairman, Novartis Pharma AG, as Chairman from 2013, Novartis Pharma BV, as Chairman, Swiss Re AG, as Vice Chairman, Novartis Foundation, as Chairman from 2013, Institut f r molekulare und klinische Ophthalmologie Basel, as Chairman-Trustees Board, Abadia Retuerta SA, as Chairman, Novartis Finance Corp, as Chairman, International Federation of Pharmaceutical Manufacturers, as Council Member from 2010, and Helmholtz-Gemeinschaft Deutscher Forschungszentren eV, as Member. Dr. Reinhardt also formerly worked at Bayer HealthCare AG, as Chairman-Management Board in 2013, Novartis Institute for Functional Genomics, Inc., as Chairman from 2000 to 2010, Lonza Group AG, as Director from 2012 to 2013, Novartis Institute for Functional Genomics, Inc., as Director, Novartis AG, as Chief Operating Officer from 2008 to 2010, MorphoSys AG, as Member-Supervisory Board from 2001 to 2004, and Sandoz Pharmaceuticals AG, as Head-Development. Dr. Reinhardt received his doctorate degree from Universit t des Saarlandes.
Charles L. Sawyers
Charles L. Sawyers is the founder of Aragon Pharmaceuticals, Inc. (2009) and Oric Pharmaceuticals, Inc. (2014). Current jobs include Chairman-Human Oncology & Pathogenesis Program at Memorial Sloan Kettering Cancer Center (2006), Independent Non-Executive Director at Novartis AG (2013), Senior Advisor at Arsenal Capital Management LP, Member at National Academy of Sciences, Member at American Academy of Arts & Sciences, Member at National Academy of Medicine (United States), Trustee at Cold Spring Harbor Laboratory, Inc., Science Partner at The Column Group LLC, and Professor at Weill Cornell Graduate School of Medical Sciences (2008). Former jobs include Chief Associate at the University of California, Los Angeles (1996-2006), President at American Association for Cancer Research (2013-2014), and President at American Society for Clinical Investigation. Education includes undergraduate degree from Princeton University and doctorate from The Johns Hopkins University School of Medicine.
William Thomas Winters
William Thomas Winters was the founder of Renshaw Bay LLP, founded in 2011, where the title held was Chief Executive Officer. Current jobs include Group Chief Executive Officer & Executive Director at Standard Chartered Plc since 2015, Chief Executive Officer at Standard Chartered Bank Ltd. since 2019, Chairman at Coronet Theatre LLC, Director at Colgate University, Director at Standard Chartered Holdings Ltd. since 2015, Director at Young Vic Theatre Co., Director at Print Room At The Coronet, Member-Market Monitoring Group at The Institute of International Finance, Inc., Member-Overseers Board at International Rescue Committee, Inc., Group Chief Executive at Standard Chartered Bank (Broker) since 2015, Member at The World Bank Group, and Member at Glasgow Financial Alliance for Net Zero. Former jobs include Co-Chief Executive Officer-Investment Bank at JPMorgan Chase & Co. from 2004 to 2009, Chief Executive Officer-Investment Bank at JPMorgan Chase & Co., Inc. from 2004 to 2010, Independent Non-Executive Director at Novartis International AG from 2015 to 2025, Non-Executive Director at RIT Capital Partners Plc, Non-Executive Director at Pension Insurance Corp. Plc in 2015, Director at Climate Impact X Pte Ltd., Independent Non-Executive Director at Novartis AG from 2013 to 2025, Commissioner at Independent Commission on Banking from 2010 to 2011, and Trustee at International Rescue Committee UK. Education includes undergraduate degree from Colgate University and MBA from The Wharton School of the University of Pennsylvania.
Nancy C. Andrews
Nancy C. Andrews is currently an Independent Director at Charles River Laboratories International, Inc. since 2020, a Director at Novartis International AG, an Independent Non-Executive Director at Novartis AG since 2015, a Director at Charles River Laboratories, Inc. since 2020, an Independent Director at Maze Therapeutics, Inc. since 2021, Chief Scientific Officer & Executive VP at The Children's Hospital Corp. since 2021, a Member of the National Academy of Medicine (United States) since 2019, a Member of the Scientific Management Review Board, a Member of MIT Corp. (United States), a Professor at Harvard Medical School since 2023, and Secretary-Home at the National Academy of Sciences since 2023. Former positions include Chairman of The Burroughs Wellcome Fund from 2011 to 2019, Chairman of the American Academy of Arts & Sciences from 2017 to 2023, Director at Duke University Health System, Inc., Program Director at Harvard Mit Health Sciences & Technology from 1999 to 2003, Professor at Duke University from 2007 to 2021, Member-Scientific Management Review Board at National Institutes of Health from 2014 to 2019, President of the American Society for Clinical Investigation, Dean at Harvard Medical School from 2003 to 2007, Dean-Emerita & Vice Chancellor-Emerita at Duke University School of Medicine from 2017 to 2021, and Trustee at Massachusetts Institute of Technology. Education includes a doctorate from Massachusetts Institute of Technology, undergraduate and graduate degrees from Yale University, and a doctorate from Harvard Medical School.
Mary Elizabeth Doherty
Mary Elizabeth Doherty is Vice Chairman-Supervisory Board at Corbion NV since 2015. She is Independent Non-Executive Director at Novartis AG since 2016. She is Independent Member-Supervisory Board at Koninklijke Philips NV since 2019. Former roles include Independent Non-Executive Director at Nokia Oyj from 2015 to 2016, Director at ABI SAB Group Holding Ltd. from 2004 to 2010, Director at Novartis International AG, Senior Independent Director at Dunelm Group Plc from 2017 to 2019, Group Director-International Finance at Tesco Plc from 2001 to 2007, Chief Financial Officer & Director at Reckitt Benckiser Group Plc from 2011 to 2012, Independent Non-Executive Director at Delhaize Le Lion from 2013 to 2016, Chief Financial Officer & Executive Director at Brambles Ltd. from 2007 to 2009, Chief Financial Officer & Executive Director at Reckitt Benckiser Ltd. from 2011 to 2013, Non-Executive Director at United Kingdom Ministry of Justice from 2015 to 2019, Non-Executive Director at Her Majesty's Courts & Tribunals Service from 2015 to 2019, Finance Director-Unilever Thai Holdings at Unilever Plc from 1981 to 2001, Member-Supervisory Board at Agrolimen SA, Chief Financial Officer at Cognita Ltd. from 2014 to 2015, Chief Financial Officer at Mint Hotel Ltd., and Chief Financial Officer at Cognita Schools Ltd. from 2014 to 2015. Education includes undergraduate degree from The University of Manchester.
旧服务已下线，请迁移至 http://api.fanyi.baidu.com
Ton Büchner
Ton Büchner is Chairman-Executive Board & Chief Executive Officer at Akzo Nobel Ltda. since 2013. Mr. Büchner is Chairman at Swiss Prime Site AG since 2020. Mr. Büchner is Independent Non-Executive Director at Novartis AG since 2016. Mr. Büchner is Director at Tonality Holding AG. Mr. Büchner is Director at Georg Fischer AG starting 2026. Mr. Büchner is Member at Ministry of Economic Affairs & Climate. Mr. Büchner is Manager at Bandinnera GmbH. Mr. Büchner is Manager at Great Apes Aviation GmbH. Formerly, Mr. Büchner was President & Chief Executive Officer at Sulzer AG from 2007 to 2011. Mr. Büchner was Chief Executive Officer at Akzo Nobel NV from 2014 to 2017. Mr. Büchner was Chairman at Burckhardt Compression Holding AG from 2020 to 2025. Mr. Büchner was Chairman at Burckhardt Compression AG from 2020 to 2025. Mr. Büchner was Director at Novartis International AG. Mr. Büchner was Member-Supervisory Board at Voith GmbH & Co. KGaA from 2014 to 2018. Mr. Büchner was President at Sulzer Turbomachinery Services from 2000 to 2002. Mr. Büchner graduated from Delft University of Technology. Mr. Büchner earned an MBA from International Institute for Management Development.
Frans van Houten
Mr. Frans van Houten is a Chairman at Castor /US/, a Chairman at Absci Corp., an Independent Non-Executive Director at Novartis AG, a Chairman-Supervisory Board at Stichting Erasmus Trustfonds (SET), a Member at European Round Table of Industrialists, a Chairman at Nl2025 and a Chief Executive Officer at Philips International BV. He is on the Board of Directors at Affidea BV, Ciwit BV, Synthesis Health, Inc., Novartis AG, FVH Capital BV, Vereniging Trustfonds Erasmus Universiteit Rotterdam and World Expo Rotterdam 2025. Mr. van Houten was previously employed as a Co-Chairman by Forum Mondial de L'Economie, a Vice Chairman-Supervisory Board by Philips Lighting NV, a Co-Chairman by Platform for Accelerating the Circular Economy, a Chief Executive Officer by Philips Lighting Holding BV, a Chairman-Supervisory Board by Erasmus University Trust Fund, a Principal by ING Groep NV, a President & Chief Executive Officer by Philips Semiconductors BV, a Chairman & Chief Executive Officer by NXP Semiconductors NV, a CEO-Consumer Electronics Businesses Group by Philips Consumer Electronics BV, a VP-International Sales & Operations by Philips Kommunikations Industrie AG, a President & Chief Executive Officer by Airvision LLC, a Chief Executive Officer by Koninklijke Philips NV, a Chief Executive Officer by Philips GmbH, and a Chief Executive Officer by Philips Lighting Electronics (Shanghai) Co. Ltd. He received his undergraduate degree from Erasmus University Rotterdam and a graduate degree from Erasmus University Rotterdam.
Patrice Bula
Mr. Patrice Bula is a Lead Independent Non-Executive Director at Novartis AG, a Chairman at Froneri Lux Topco SARL, a Vice Chairman at Schindler Holding AG, a Chairman at Beverage Partners Worldwide (Europe) AG, a Chairman at European Pizza Group Bidco SARL, a Chairman at Froneri International Ltd., a Chairman at Shanghai Totole Flavouring Food Co. Ltd. and a Market Head at Nestlé (China) Ltd. He is on the Board of Directors at Novartis AG, Schindler Holding AG, Life Ventures SA, New Tiger International, Inc. and Tiger LLC. Mr. Bula was previously employed as a Chairman by Blue Bottle Coffee, Inc., a Co-Chairman by Cereal Partners Worldwide SA, a Head-Market by Nestlé Deutschland AG, a Chief Executive Officer by Cokoladovny AS, a Marketing Director by Nestlé Taiwan Ltd., a Manager-Food Business Unit by Nestlé Japan Ltd., a Chairman by Nestlé Nespresso SA, and an EVP, Head-Strategic Sales & Marketing by Nestlé SA. He also served on the board at Bobst Group SA, Hsu Fu Chi Holdings Ltd., Froneri Ltd. and Nutrition-Wellness Venture AG. He received his graduate degree from the University of Lausanne.
Bridgette P. Heller
Bridgette P. Heller was the founder of Heller Associates, Inc., founded in 2004, where the title held was Managing Partner from 2004 to 2005. Ms. Heller is the founder of Shirley Proctor Puller Foundation, founded in 2019, holding the title Chief Executive Officer & Director since 2019. Current jobs include Director at Newman's Own Foundation since 2021, Independent Non-Executive Director at Novartis AG since 2020, Independent Director at DexCom, Inc. since 2019, Director at Newman's Own, Inc. since 2020, Director at Market Track LLC since 2021, Independent Director at Aramark since 2021, Trustee at Northwestern University Clinical & Translational Sciences Inst, and Partner at Seedfunders LLC. Former jobs include Chief Executive Officer at Chung's Foods, Inc. from 2003 to 2004, Chairman at Girls, Inc. from 2008 to 2012, Independent Director at Integral Ad Science Holding Corp. from 2021 to 2025, Independent Director at Tech Data Corp. from 2016 to 2020, Director at The ADT Security Corp. from 2012 to 2016, Director at PCA International, Inc. in 2005, Director at Integral Ad Science, Inc. from 2021 to 2025, President-Consumer Care & Executive VP at Merck & Co., Inc. from 2010 to 2015, President-Baby Global Business Unit at Johnson & Johnson from 2007 to 2010, Executive Vice President & GM-Coffee Division at Mondelez International, Inc. from 1985 to 2002, EVP & GM-North American Coffee Portfolio at Kraft Foods Group, Inc. from 1985 to 2002, President & Executive Vice President at Nutricia Holdings Plc from 2016 to 2019, Executive VP & President-Specialized Nutrition at Danone Nederland BV from 2017 to 2019, President at Merck-Consumer Care from 2010 to 2015, and President-Specialized Nutrition & Executive VP at Danone SA from 2017 to 2019. Education includes an MBA degree from Kellogg School of Management conferred in 1985.
Simon E. Moroney
Simon E. Moroney was the founder of MorphoSys AG, founded in 1992, where the title held was Chief Executive Officer from 1992 to 2019. Current jobs include Vice Chairman at Novartis AG since 2022 and Chairman at Biotalys NV since 2021. Former jobs include Director-Supervisory Board at ProtAffin Biotechnologie AG from 2009 to 2011, President at the Government of Germany, Research Associate at the University of Cambridge from 1991 to 1992, Associate-Chemistry Department at Swiss Federal Institute of Technology from 1986 to 1989, Associate at Harvard Medical School from 1984 to 1986, and Assistant Professor at the University of British Columbia from 1989 to 1990. Education history includes a doctorate from the University of Oxford conferred in 1984 and a graduate degree from Waikato University conferred in 1981.
Ana de Pro Gonzalo
Ana de Pro Gonzalo is currently Independent Non-Executive Director at Novartis AG since 2022, Independent Non-Executive Director at Mobico Group Plc since 2019, Member-Supervisory Board at STMicroelectronics NV since 2020, Member-Supervisory Board at Global Steering Group since 2020, and Trustee at Juan Xxiii Foundation since 2020. Former roles include Non-Executive Director at Indra Sistemas SA from 2020 to 2022, Non-Executive Director at Amadeus IT Group SA in 2020, Independent Non-Executive Director at MERLIN Properties SOCIMI SA from 2015 to 2017, General Manager at Sacyr SA from 2002 to 2010, Chief Financial Officer & Deputy General Manager at Metrovacesa SA from 1994 to 2002, and Senior Auditor at Arthur Andersen Y Compania from 1990 to 1994. Education includes undergraduate studies at Universidad Complutense de Madrid.
John D. Young
John D. Young is Director at Johnson Controls, Inc., Independent Non-Executive Director at Novartis AG since 2023, Independent Director at Johnson Controls International Plc since 2017, Member of the Ministerial Industry Strategy Group since 2008, and Member of the Life Sciences Council. Former roles include Chairman & Managing Director at Pfizer Ltd., Independent Director at Arvinas, Inc. from 2022 to 2025, Director at Biotechnology Innovation Organization from 2018 to 2021, Director at European Federation of Pharmaceutical Industries & Assns from 2012 to 2017, Director at Imbria Pharmaceuticals, Inc. from 2022 to 2024, Non-Executive Director at Haleon Plc from 2022 to 2023, Chief Business Officer at Pfizer Inc. from 2019 to 2021, President at Hospira, Inc., Group President at Pfizer Essential Health from 2016 to 2018, and Member of the National Committee on United States-China Relations, Inc. from 2014 to 2017. Education includes undergraduate studies at the University of Glasgow and an MBA from Strathclyde Business School.
Charles Swanton
Charles Swanton is the founder of Achilles Therapeutics Plc, founded in 2020, with no titles listed. Dr. Swanton is the founder of Achilles Therapeutics UK Ltd., founded in 2016, with no titles listed. Dr. Swanton is the founder of The Francis Crick Institute Ltd., founded in 2016, holding the title of Deputy Director-Clinical since 2023. Dr. Swanton is also the founder of University College London. Current jobs include Director at American Association for Cancer Research since 2019, Director at Bicycle Therapeutics Plc since 2025, and Director at Novartis AG starting in 2026. Former jobs include Co-Director-Lung Cancer Centre of Excellence at Cancer Research UK and a position at UCL Medical School. Education includes undergraduate studies at UCL Medical School and both undergraduate and doctorate degrees from University College London.